Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLRS NASDAQ:LIXT NASDAQ:TVRD NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$4.33-0.7%$5.35$2.14▼$11.88$103.02M0.1570,075 shs34,257 shsLIXTLixte Biotechnology$6.19-14.6%$4.80$0.64▼$7.51$92.97M1.27211,115 shs871,824 shsTVRDTvardi Therapeutics$2.64-2.6%$3.31$2.61▼$43.65$24.77M0.3353,353 shs36,817 shsVRCAVerrica Pharmaceuticals$5.73-5.0%$6.28$3.28▼$9.82$98.44M1.4939,756 shs49,862 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics-0.69%-2.48%-10.35%-50.06%+49.31%LIXTLixte Biotechnology-14.62%-11.57%+23.80%+99.04%+403.25%TVRDTvardi Therapeutics-2.58%-8.65%-33.16%-32.65%-89.93%VRCAVerrica Pharmaceuticals-4.98%-5.13%-22.25%-6.22%-8.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$4.33-0.7%$5.35$2.14▼$11.88$103.02M0.1570,075 shs34,257 shsLIXTLixte Biotechnology$6.19-14.6%$4.80$0.64▼$7.51$92.97M1.27211,115 shs871,824 shsTVRDTvardi Therapeutics$2.64-2.6%$3.31$2.61▼$43.65$24.77M0.3353,353 shs36,817 shsVRCAVerrica Pharmaceuticals$5.73-5.0%$6.28$3.28▼$9.82$98.44M1.4939,756 shs49,862 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics-0.69%-2.48%-10.35%-50.06%+49.31%LIXTLixte Biotechnology-14.62%-11.57%+23.80%+99.04%+403.25%TVRDTvardi Therapeutics-2.58%-8.65%-33.16%-32.65%-89.93%VRCAVerrica Pharmaceuticals-4.98%-5.13%-22.25%-6.22%-8.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLRSKalaris Therapeutics 2.75Moderate Buy$15.60260.28% UpsideLIXTLixte Biotechnology 1.00SellN/AN/ATVRDTvardi Therapeutics 2.50Moderate Buy$39.801,407.58% UpsideVRCAVerrica Pharmaceuticals 2.25Hold$14.50153.05% UpsideCurrent Analyst Ratings BreakdownLatest TVRD, KLRS, LIXT, and VRCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/8/2026TVRDTvardi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026VRCAVerrica Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/11/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/16/2026KLRSKalaris Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$14.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ATVRDTvardi Therapeutics$7.14M3.47N/AN/A$2.23 per share1.18VRCAVerrica Pharmaceuticals$35.58M2.77N/AN/A$1.55 per share3.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ALIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ATVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/AVRCAVerrica Pharmaceuticals-$17.89M-$1.03N/AN/AN/A-47.97%-1,077.78%-40.76%8/11/2026 (Estimated)Latest TVRD, KLRS, LIXT, and VRCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/A3/31/2026Q4 2025TVRDTvardi Therapeutics-$0.55-$0.78-$0.23-$0.78N/AN/A3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLRSKalaris TherapeuticsN/A12.1912.19LIXTLixte BiotechnologyN/A2.782.78TVRDTvardi TherapeuticsN/A2.252.25VRCAVerrica Pharmaceuticals0.032.101.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLRSKalaris Therapeutics66.05%LIXTLixte Biotechnology5.10%TVRDTvardi Therapeutics44.66%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipKLRSKalaris Therapeutics68.10%LIXTLixte Biotechnology9.50%TVRDTvardi Therapeutics7.40%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLRSKalaris Therapeutics11023.79 million7.59 millionN/ALIXTLixte Biotechnology415.02 million13.59 millionNot OptionableTVRDTvardi Therapeutics809.38 million8.69 millionN/AVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataTVRD, KLRS, LIXT, and VRCA HeadlinesRecent News About These CompaniesUnited Therapeutics (NASDAQ:UTHR) vs. Verrica Pharmaceuticals (NASDAQ:VRCA) Head-To-Head AnalysisJune 7, 2026 | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Rating of "Hold" from AnalystsJune 6, 2026 | americanbankingnews.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comVerrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 13, 2026 | uk.finance.yahoo.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comVerrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2026 | zacks.comVerrica Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6, 2026 | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5, 2026 | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5, 2026 | bakersfield.comBVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 19, 2026 | tmcnet.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 19, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVRD, KLRS, LIXT, and VRCA Company DescriptionsKalaris Therapeutics NASDAQ:KLRS$4.33 -0.03 (-0.69%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$4.42 +0.09 (+2.06%) As of 06/12/2026 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Lixte Biotechnology NASDAQ:LIXT$6.19 -1.06 (-14.62%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.42 +0.23 (+3.80%) As of 06/12/2026 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Tvardi Therapeutics NASDAQ:TVRD$2.64 -0.07 (-2.58%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.65 +0.01 (+0.38%) As of 06/12/2026 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Verrica Pharmaceuticals NASDAQ:VRCA$5.73 -0.30 (-4.98%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$5.72 -0.01 (-0.17%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
